ArticleJournal of addiction medicine
Medicaid Unwinding: Association With New and Ending Buprenorphine Treatment Episodes.
Article in Journal of addiction medicine. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Association of Coverage-Promoting Policies With Initiation and Discontinuation of Buprenorphine Treatment During Medicaid Unwinding.Journal of addiction medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
importanceMedicaid is an important source of coverage for buprenorphine treatment for opioid use disorder (OUD). The loss of Medicaid coverage through Medicaid unwinding may substantially impact individuals' ability to initiate and continue buprenorphine, but little is known about how Medicaid unwinding is associated with buprenorphine OUD treatment.
objectiveExamine the association of Medicaid unwinding overall and by magnitude of unwinding with changes in buprenorphine OUD treatment. DESIGN, SETTING, AND
participantsRetrospective cohort study using 2021-2023 national retail pharmacy data on dispensed buprenorphine prescriptions. EXPOSURE: Magnitude of Medicaid disenrollment in the 6 months after unwinding began. MAIN OUTCOMES AND MEASURES: Average monthly change in new and ending buprenorphine treatment episodes, defined as starting buprenorphine treatment after 30 days without buprenorphine and ending after 30 days without buprenorphine. Statistical significance was assessed using 95% CI constructed from 2-sample t tests.
resultsMedicaid unwinding was associated with increases in Medicaid buprenorphine episodes ending (+3.0%, 95% CI: -1.1, 7.0, n=+5350) and decreases in new Medicaid episodes (-2.6%, 95% CI: -5.3, 0.1, n=-5756). The greatest changes were in states with the greatest disenrollment (+5.5%, 95% CI: 0.8, 10.1; n=+2320 for episodes ending and -3.9%, 95% CI: -7.3, -0.6; n=-1843 for episodes starting). Changes in Medicaid-covered episodes were not offset by other payers: among all payers, we observed an increase in episodes ending (+2.7%, 95% CI: 1.9, 3.4, n=+10,300) and a negligible increase in new episodes (+0.1%, 95% CI: -0.7, 1.0, n=+570). CONCLUSIONS AND RELEVANCE: Medicaid unwinding may have resulted in substantial disruptions to buprenorphine treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.